Document is current

Article History

Received: 22 May 2018

Accepted: 10 December 2018

First Online: 20 December 2018

Ethics approval and consent to participate

: This retrospective, observational, multicentre study was conducted after requesting the approval of the National Medical Ethics Committee of Slovenia. We retrospectively identified in our medical records all patients who were started on intravitreal aflibercept between October 2013 and April 2015 for the indication of treatment-naïve nAMD in at least one eye. At the time all treatments were conducted in four centres, which provided data for this analysis. It is the participating hospitals’ policy that, prior to starting treatment, all patients are requested to provide written consent to the use of their anonymised data for the purposes of clinical audit and research. All patients treated in Slovenia during this period, and included in this analysis, provided their written informed consent.

: Not applicable for this section.

: Prof Polona Jaki Mekjavic: honoraria for consultancy from Novartis, Bayer and Alcon. Dr. Bogdan Gregorčič and Dr. Slava Podgoršek: honoraria for consultancy from Novartis and Bayer. Dr. Cvetka Oberč does not have any conflict of interest with this submission.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.